MEDICAL PROFESSIONALS

Can catheter ablation cure
Afib?

 

Interview Dr Richard Schilling

 

Afib can cause strokes and heart failure. With much treatment only a temporary alleviance, and open-heart surgery a major risk, Dr Richard Schilling, of St Barts Hospital, raises the possibility that catheter ablation may bring hope for this common problem.

 

Atrial fibrillation (Afib) is sustained cardiac arrhythmia, affecting 6 per cent of the population over the age of 65. It is the leading cardiac cause of stroke and increases the risk of stroke five-fold. It is also associated with heart failure and consequently is a considerable burden on health service resources.

 

The ventricular rate can be controlled either by using anti arrhythmic drugs or by catheter ablation of the atrioventricular (AV) node and pacemaker implantation. However, this does not restore atrial transport nor does it eliminate the risk of embolic strokes, even with the use of anticoagulants. Therefore, restoring and maintaining sinus rhythm (SR) is the optimal treatment.

 

One of the most exciting and promising treatments for the cure of Afib is the use of catheters to apply radiofrequency energy to the atrial tissue. This modifies the electrical properties of the atrium in order to eliminate the tendency to fibrillate.

 

There is increasing confusion regarding the results and benefits of catheters for Afib because of the rapidly evolving techniques, and a wide range of opinion and recommendations regarding its efficacy. The number of catheter ablation procedures is increasing dramatically. An apparently chaotic heart rhythm is amenable to cure, and in order to understand how, the currently employed catheter techniques must be reviewed.

 

 

Paroxysmal, persistent and permanent

Afib is usually prefixed by a temporal descriptive term. Paroxysmal Afib terminates spontaneously. Persistent Afib describes Afib lasting for more than seven days or requiring some intervention to terminate it. Permanent Afib is resistant to all conventional interventions to terminate it. These conventional interventions include anti-arrhythmic drug therapy and direct current cardioversion.

 

back to top

 

Underlying mechanisms

The mechanism of Afib is not clearly understood. The most commonly accepted mechanism underlying Afib is multiple, random waves of electrical depolarisation. These waves follow re-entry circuits around lines of conduction block in the atria, which may be fixed (present all the time, like anatomical structures such as veins) or functional (only present under certain circumstances, depending on the conduction property of the myocardium).

 

It has become apparent, however, that the initiating event is the presence of rapidly firing premature atrial beats, which most often arise from atrial tissue within the pulmonary veins, the veins that drain blood from the lungs into the left atrium. These are called focal ectopic tachycardias. In some patients it has also been observed that this rapidly firing focal activity can also be responsible for maintaining Afib as well as initiating it. This focal activity gives cardiologists a potential target for curative catheter ablation for the first time.

 

 

back to top

 

Catheter ablation of Afib

Curative ablation of Afib has evolved to encompass two goals: removing all potential triggers that may initiate or perpetuate Afib and altering the conduction properties of the atria (substrate modification) so that Afib cannot be sustained even when triggered. It has become apparent that patients have a wide range of mechanisms for their atrial fibrillation and the clinical presentation is a crude and imperfect guide to the possible mechanism. For example, those patients presenting with frequent non-sustained episodes of Afib are more likely to have a repetitive trigger leading to their problems. In contrast, the abnormal electrophysiological properties of the atrium are likely to be more important in patients with permanent Afib. The recognition of the range of mechanisms depending on type of Afib has allowed procedures to be tailored so that, for example, in paroxysmal Afib only an isolation of triggers is attempted and not the more complex substrate modification.

 

 

back to top

 

Abolition of triggers

The most common sources of triggers are the pulmonary veins (PVs), but up to 20 per cent may be non-PV in origin, such as the superior vena cava, coronary sinus or crista terminalis. These triggers are rarely active during a catheter ablation procedure, so the approach to catheter ablation is to treat the most common aetiology, the PVs. The trigger sites are isolated from the rest of the atria either by destroying the muscular connections that link them to the atria or creating a continuous line of conduction block in the atria that surrounds and encloses them. This is done in two ways: either by delivering energy close to the vein origin or creating a wide circle of energy application which encloses ipsilateral vein origins. Although there remains controversy as to whether true electrical disconnection is necessary to achieve success, most key opinion leaders believe that it is. In order to confirm electrical isolation, a circular mapping catheter is advanced to the pulmonary veins and used to record electrical activity. When the electrograms on the mapping catheter disappear, the vein is isolated.

 

Using ablation to abolish triggers produces excellent results (51-100 per cent freedom from Afib). However the methods and reporting of observational studies vary greatly.

 

 

back to top

 

Substrate modification

There are two approaches to substrate modification. Firstly it can be achieved by creating transmural linear lesions that connect two anatomical structures and form barriers to conduction, thus interrupting the re-entry circuits that perpetuate Afib. The alternative approach (also known as atrial debulking) is to reduce the amount of atrial tissue available to form re-entry wavefronts, either by enclosing and isolating large areas of atrial tissue (typically done around the PVs) or ablating widely all over the atria, thus reducing the amount of viable tissue. This is usually done with the assistance of a non-fluoroscopic mapping system.

 

These systems allow three-dimensional imaging of the ablation catheter without the need for x-rays and allow accurate placement of lesions within the atria, but also provide a record of where lesions have already been placed. A possible downside to substrate modification is the reduction in the contractile potential of the atria, which may prevent recovery of mechanical function. However in studies describing cardiac function after such procedures the cardiac function actually improves. This is probably the result of restoration of atrial contraction and a reflection of the fact that most ablation is performed at areas of the atrium which are non-contractile such as the PV os.

 

It is clear from observational studies that PV isolation alone is not as effective for patients with persistent or permanent Afib in comparison with paroxysmal Afib, which is consistent with the current understanding of the mechanisms described above. Initial attempts at delivering long lines of radiofrequency ablation to connect anatomical obstacles, although successful, led to high complication rates. Wide encirclement success has been reported as high as 68 per cent freedom from permanent Afib and 73 per cent from non-paroxysmal Afib. With the addition of proven electrical isolation even permanent Afib can be successfully abolished in 79 per cent of patients after multiple procedures. However, achieving this is technically challenging and requires long, arduous procedures. In addition, gaps in these lines may promote regular atrial tachycardias, which use the ablation lines as their pathway.

 

An alternative approach has been the ablation of all fragmented electrical activity in the right and left atrium, with the hypothesis being that these are consistent sites where fibrillating wavefronts turn or split. By ablating these areas, the propagating random wavefronts are progressively restricted until the atria can no longer support Afib. It is not clear whether the success of this technique is related simply to debulking myocardium or to targeting the critically positioned electrograms.

 

 

back to top

 

New technologies

A number of technological advances have contributed to the increased success of Afib ablation, but probably the most significant are advancements in three-dimensional catheter imaging technologies. It is now possible to import and register a three-dimensional CT or MRI scan into a catheter imaging system so that the catheter can be manipulated in a three-dimensional rendering of the patients left atrium. Other technologies, such as the use of ultrasound balloons to isolate the veins, show promise but are still under development and unproven.

 

 

back to top

 

Complications of catheter ablation

For the 9000 patients in the worldwide survey of Afib ablation, there was a mortality of 0.05 per cent and an overall complication rate of 5.9 per cent. However, some of the largest interventional centres did not contribute to this study and published single centre studies report the incidence of complications at <1 per cent for paroxysmal Afib. When linear ablation is attempted a higher rate is expected.

 

Stroke and pericardial tamponade are understandable risks of a procedure that involves multiple transseptal punctures and the delivery of radiofrequency energy within the systemic circulation. These can be minimised by good technique and training. latrogenic PV stenosis is a clinical condition that is created as a result of delivering too much energy through the PVs. Symptoms of progressive dyspnoea, cough and haemoptysis are insidious and can be wrongly diagnosed as respiratory pathology. Remarkably, patients are usually asymptomatic unless more than one PV is occluded or severely stenosed. Although it can be successfully treated by angioplasty, it is best avoided. The development of an atrio-oesophageal fistula is a very rare but lethal complication. Presentation is with pericarditis, sepsis (suspected endocarditis) or massive haematemesis. Even prompt surgical intervention may fail to recover the patient.

 

Catheter ablation

  • cures Afib
  • avoids open-heart surgery
  • abolishes Afib triggers
  • mortality rate of 0.05 per cent
  • complication rate of 5.9 per cent

 

 

back to top

 

Who to refer for ablation?

At the present time there is strong evidence that catheter ablation is successful in abolishing Afib in patients even when they are refractory to conventional therapy. There is no large randomised controlled trial evidence yet that reduces stroke risk or improves mortality, but trials comparing it to drug therapy as first line therapy for Afib have already shown catheter ablation to be superior. Patients who are suitable to catheter ablation are those that are symptomatic and many centres insist that they try conventional therapy before proceeding to catheter ablation.

 

For many patients with a previously untreatable heart rhythm, ablation has delivered dramatic improvement in their symptoms by restoring and maintaining sinus rhythm. Although there are significant risks associated with these procedures, many patients are more than willing to accept these. Whether the serious and previously underestimated risks associated with Afib, such as stroke, heart failure and death, are abolished by catheter ablation remains to be proven.

 

 

back to top

 

Author

Dr Richard Schilling is a consultant cardiologist and electrophysiologist at St Barts Hospital, London, and senior lecturer at Queen Mary's College, University of London. He has a research interest in AF and arrhythmia arising in congenital heart disease.

 

back to top

 

©Johnson & Johnson Medical NV/SA, 2010. Last update on:03 Feb 2012 This site is published by Johnson & Johnson Medical NV/SA, which is solely responsible for its contents. This section of the website is intended for visitors from the European Economic Area (EEA), excluding France. The EEA includes the 25 EU member states and Norway, Iceland, and Liechtenstein. Capitalized product names are trademarks of Biosense Webster.